CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $13.39M, lower than 95% of all stocks globally
- PositionGross margin is -302.7%, lower than 95% of its Biotechnology peers (median 77.2%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.73BUSDvs all stocks (USD)
Revenue (TTM)
13.39MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.74xvs all stocks
52-Week Change
11.65%vs all stocks
Market Capitalization
5.73BUSDvs all stocks (USD)
Enterprise Value
4.31BUSDvs all stocks (USD)
Forward P/E
-17.41xvs Biotechnology peers
Price to Book (MRQ)
3.37xvs Biotechnology peers
Enterprise to Revenue
321.68xvs Biotechnology peers
Enterprise to EBITDA
-8.39xvs Biotechnology peers
Gross Margin
-302.72%vs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-1127.55%vs Biotechnology peers
Return on Assets (TTM)
-14.20%vs Biotechnology peers
Return on Equity (TTM)
-26.10%vs Biotechnology peers
Revenue (TTM)
13.39MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.1410USDUpdated Aug 27, 2026Quarterly Revenue Growth
1041.40%vs Biotechnology peers
Gross Profit (TTM)
-461.80MUSDvs all stocks (USD)
EBITDA (TTM)
-513.17MUSDvs all stocks (USD)
Net Income (TTM)
-451.14MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-369.58MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-215.85MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Aug 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Cost of Goods Sold
213.48MUSDFY2025 · Dec 31, 2025Gross Profit
-213.48MUSDFY2025 · Dec 31, 2025Operating Income
-664.57MUSDvs all stocks (USD)
Pre-tax Income
-577.97MUSDFY2025 · Dec 31, 2025Income Tax Expense
3.63MUSDFY2025 · Dec 31, 2025Net Income
-581.60MUSDFY2025 · Dec 31, 2025EBIT
-664.57MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-645.09MUSDFY2025 · Dec 31, 2025Research & Development
381.06MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
73.54MUSDFY2025 · Dec 31, 2025Other Operating Expenses
-3.51MUSDFY2025 · Dec 31, 2025EPS (Basic)
-6.47USDFY2025 · Dec 31, 2025EPS (Diluted)
-6.47USDFY2025 · Dec 31, 2025Basic Shares Outstanding
89.93MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
89.93MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-581.60MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-393.25MUSDFY2025 · Dec 31, 2025Free Cash Flow
-394.16MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
359.08MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-581.60MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
19.48MUSDFY2025 · Dec 31, 2025Stock-based Compensation
72.50MUSDFY2025 · Dec 31, 2025Other Non-cash Items
72.72MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
25.00MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.35MUSDFY2025 · Dec 31, 2025Capital Expenditures
-914.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-25.00MUSDFY2025 · Dec 31, 2025Purchase of Investments
-1.02BUSDFY2025 · Dec 31, 2025Sale of Investments
1.01BUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-6.80MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
398.09MUSDFY2025 · Dec 31, 2025Shares Outstanding
96.66MSharesUpdated Aug 27, 2026Float Shares
96.27MSharesUpdated Aug 27, 2026Shares Short
18.74MSharesUpdated Aug 27, 2026Short Ratio
12.77daysvs all stocks
Short % of Shares Outstanding
22.20%vs all stocks
% Held by Insiders
5.89%vs all stocks
% Held by Institutions
77.86%vs all stocks
Total Cash (MRQ)
2.36BUSDvs all stocks (USD)
Total Cash per Share (MRQ)
24.45USDUpdated Aug 27, 2026Total Debt (MRQ)
783.75MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.4487xvs Biotechnology peers
Current Ratio (MRQ)
17.85xvs Biotechnology peers
Book Value per Share (MRQ)
18.07USDUpdated Aug 27, 2026Total Assets
2.27BUSDvs all stocks (USD)
Total Current Assets
1.99BUSDFY2025 · Dec 31, 2025Total Liabilities
343.43MUSDFY2025 · Dec 31, 2025Total Non-current Assets
279.57MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
194.31MUSDFY2025 · Dec 31, 2025Total Current Liabilities
149.12MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
347.56MUSDFY2025 · Dec 31, 2025Other Short-term Investments
1.63BUSDFY2025 · Dec 31, 2025Accounts Receivable
0.00USDFY2025 · Dec 31, 2025Accounts Payable
11.14MUSDFY2025 · Dec 31, 2025Short-term Debt
18.58MUSDFY2025 · Dec 31, 2025Deferred Revenue
15.77MUSDFY2025 · Dec 31, 2025Other Current Liabilities
13.11MUSDFY2025 · Dec 31, 2025Long-term Debt
188.17MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
6.14MUSDFY2025 · Dec 31, 2025Common Stock (Book)
3.09MUSDFY2025 · Dec 31, 2025Retained Earnings
-1.95BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.92BUSDvs all stocks (USD)
Treasury Stock
60.00KUSDFY2025 · Dec 31, 202552-Week Low
44.12USDUpdated Aug 27, 202652-Week High
78.48USDUpdated Aug 27, 202652-Week Change
11.65%vs all stocks
Beta
1.74xvs all stocks
50-Day MA
52.91USDUpdated Aug 27, 2026200-Day MA
53.09USDUpdated Aug 27, 2026Avg 10-Day Volume
1.71MSharesUpdated Aug 27, 2026Avg 30-Day Volume
1.61MSharesUpdated Aug 27, 2026Diluted EPS (TTM)
-5.02USDUpdated Aug 27, 2026Other Income / Expense
86.61MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is -302.7%, lower than 95% of its Biotechnology peers (median 77.2%)Significant
Gross margin: -3.03Industry median: 0.77Industry P5: 0.18Peers compared: 194
Financial Health
Altman Z-Score 8.81: safe zoneNotable
Altman Z-Score: 8.81
High structural barrier to entryNotable
Barrier to Entry: 186.592
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $13.39M, lower than 95% of all stocks globallySignificant
Revenue (USD): 13,392,000Global P5: 32,166,921.735
Levered free cash flow is -$215.85M, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -215,845,872Global P5: -209,187,555.994
Market cap is $5.73B, above the global median of $1.18BNotable
Market cap (USD): 5,727,105,837Global Median: 1,179,398,897.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanghai Junshi Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Salubris Pharmaceuticals Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Xenon Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Definium Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
APT Medical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ptc Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Mirum Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sectra AB
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Zhejiang Hisun Biomaterials Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
HBL Engineering Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Olaplex Holdings, Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity